Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImExHS Limited ( (AU:IME) ) has shared an update.
ImExHS Limited has reported a change in the interests of director Douglas Flynn, detailing an internal reorganisation of his indirect holdings in the company’s shares. The transaction involved an off-market sale of 2,181,418 fully paid ordinary shares from a Flynn-related superannuation entity to another Flynn-associated company at $0.41 per share, leaving his overall exposure to ImExHS largely intact but redistributed across his controlled entities.
Following the transaction, Flynn continues to hold a mix of direct options and substantial indirect shareholdings through multiple vehicles, including DR & LC Flynn Nominees Pty Limited, Dai Yat Pty Ltd, and Auxino Partners Pty Ltd. The reshuffling of these interests appears to be a structural adjustment rather than a full divestment, signalling ongoing alignment between the director and shareholders while clarifying the configuration of his economic stake in ImExHS.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
ImExHS Limited is an Australian-listed company active in the healthcare technology sector, focusing on imaging and related medical software solutions. The company operates in markets that require advanced diagnostic imaging platforms and associated services, positioning itself within the broader medical technology and health IT industry.
Average Trading Volume: 29,803
Technical Sentiment Signal: Sell
Current Market Cap: A$20.82M
For a thorough assessment of IME stock, go to TipRanks’ Stock Analysis page.